Carter-Wallace Felbatol (correction)
Executive Summary
Carter-Wallace's Felbatol (felbamate) is restricted to second-line use in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children due to risk of aplastic anemia and liver failure. "The Pink Sheet" (Aug. 27, p. 29) incorrectly reported that Felbatol had been withdrawn
You may also be interested in...
MedPointe To Seek Fluorofelbamate Partner After Carter-Wallace Acquisition
MedPointe will likely seek a development partner for the anti-epileptic fluorofelbamate after the company acquires Carter-Wallace's healthcare business.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials